RS50933B - Izoindolin-1-on aktivatori glukokinaze - Google Patents

Izoindolin-1-on aktivatori glukokinaze

Info

Publication number
RS50933B
RS50933B YUP-477/03A YUP47703A RS50933B RS 50933 B RS50933 B RS 50933B YU P47703 A YUP47703 A YU P47703A RS 50933 B RS50933 B RS 50933B
Authority
RS
Serbia
Prior art keywords
ring
alkyl
membered
monosubstituted
carbon atoms
Prior art date
Application number
YUP-477/03A
Other languages
English (en)
Inventor
Kevin Richard Guertin
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of YU47703A publication Critical patent/YU47703A/sh
Publication of RS50933B publication Critical patent/RS50933B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Jedinjenje formule:naznačeno time stoA predstavlja nesupstituisani fenil ili fenil koji može biti mono- ili disupstituisan halogenom ili monosupstituisan C1-C10-alkil sulfonil, C1-C10-alkil tio ili nitro grupom;R1 predstavlja cikloalkil sa 3 do 9 atoma ugljenika ili alkil sa 2 do 4 atoma ugljenika;R2 predstavlja neki nesupstituisani ili monpsupstituisani petočlani ili šestočlani heteroaromatični prsten, koji je preko atoma ugljenika iz prstena povezan sa prikazanom amino grupom, pri čemu petočlani ili šestočlani heteroaromatični prsten sadrži 1 do 3 heteroatoma izabrana između sumpora, kiseonika ili azota, od kojih je jedan od heteroatoma azot koji je pored vezujućeg atoma ugljenika iz prstena, pri čemu je prsten monocikličan ili fuzionisan sa fenilom preko dva od svojih atoma ugljenika iz prstena, pri čemu je pomenuti monosupstituisani heteroaromatični prsten monosupstituisan na poziciji ugljenika iz prstena različitoj od one pored vezujućeg atoma ugljenika, i to supstituentom izabranim iz grupe koja se sastoji od halogena, C1-C10-alkil, nitro, cijano, perfluoro-C1-C10-alkil; hidroksi, -(CH2)n-OR3, -(CH2)n-C(O)-OR3, -(CH2)n-C(O)-NH-R3, -C(O)C(O)-OR3 ili (CH2)n-NHR3; R3 je vodonik ili C1-C10-alkil; a n je 0, 1,2,3 ili 4;ili njegove farmaceutski prihvatljive soli ili N-oksidi.Prijava sadrži još 19 patentnih zahteva.
YUP-477/03A 2000-12-13 2001-12-07 Izoindolin-1-on aktivatori glukokinaze RS50933B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13

Publications (2)

Publication Number Publication Date
YU47703A YU47703A (sh) 2006-05-25
RS50933B true RS50933B (sr) 2010-08-31

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-477/03A RS50933B (sr) 2000-12-13 2001-12-07 Izoindolin-1-on aktivatori glukokinaze

Country Status (36)

Country Link
US (1) US6482951B2 (sr)
EP (1) EP1349856B1 (sr)
JP (1) JP4021766B2 (sr)
KR (1) KR100520651B1 (sr)
CN (1) CN1247574C (sr)
AT (1) ATE297922T1 (sr)
AU (2) AU3841502A (sr)
BG (1) BG107903A (sr)
BR (1) BR0116169A (sr)
CA (1) CA2430579C (sr)
CY (1) CY1105587T1 (sr)
CZ (1) CZ20031882A3 (sr)
DE (1) DE60111570T2 (sr)
DK (1) DK1349856T3 (sr)
EG (1) EG24358A (sr)
ES (1) ES2243578T3 (sr)
HK (1) HK1063314A1 (sr)
HR (1) HRP20030450B1 (sr)
HU (1) HUP0400587A3 (sr)
IL (2) IL156264A0 (sr)
MA (1) MA26973A1 (sr)
MX (1) MXPA03005170A (sr)
MY (1) MY136741A (sr)
NO (1) NO325810B1 (sr)
NZ (1) NZ526236A (sr)
PA (1) PA8534601A1 (sr)
PE (1) PE20020593A1 (sr)
PL (1) PL366006A1 (sr)
PT (1) PT1349856E (sr)
RS (1) RS50933B (sr)
RU (1) RU2249590C2 (sr)
SI (1) SI1349856T1 (sr)
SK (1) SK8732003A3 (sr)
TW (1) TWI294876B (sr)
UY (1) UY27069A1 (sr)
WO (1) WO2002048106A2 (sr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE60316709T2 (de) 2002-10-03 2008-07-17 F. Hoffmann-La Roche Ag Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
AU2003302279B2 (en) 2002-10-03 2008-06-12 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of Type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
RU2006138426A (ru) * 2004-04-02 2008-05-10 Новартис АГ (CH) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
CA2621227A1 (en) * 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
JP2009513711A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン
JP2009513704A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン
CN101321747A (zh) * 2005-11-01 2008-12-10 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的环烷基吡咯酮类
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
WO2007104034A2 (en) * 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ATE522518T1 (de) * 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
EP2091947A2 (en) * 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8034819B2 (en) 2007-03-07 2011-10-11 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
WO2009092432A1 (en) * 2008-01-24 2009-07-30 Merck Patent Gmbh Beta-amino acid derivatives for treatment of diabetes
PL2275414T3 (pl) 2008-04-28 2016-01-29 Kyorin Seiyaku Kk Pochodne cyklopentyloakryloamidu
WO2009140624A2 (en) 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
CN102216276A (zh) * 2008-09-11 2011-10-12 辉瑞大药厂 取代的杂芳基物
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcアゴニストの調製方法
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
RS59663B1 (sr) * 2013-05-27 2020-01-31 Hoffmann La Roche Nova jedinjenja 3,4-dihidro-2h-izokinolin-1-on i 2,3-dihidro-izoindol-1-on
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
DK1280801T3 (da) 2000-05-03 2006-01-23 Hoffmann La Roche Hydantoinholdige glucokinaseaktivatorer
MXPA02010796A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa.

Also Published As

Publication number Publication date
EP1349856A2 (en) 2003-10-08
SI1349856T1 (en) 2005-10-31
HK1063314A1 (en) 2004-12-24
CN1247574C (zh) 2006-03-29
IL156264A (en) 2010-11-30
HUP0400587A3 (en) 2011-03-28
EG24358A (en) 2009-03-04
CZ20031882A3 (cs) 2003-12-17
DK1349856T3 (da) 2005-10-17
CY1105587T1 (el) 2010-07-28
BG107903A (bg) 2004-02-27
MY136741A (en) 2008-11-28
KR100520651B1 (ko) 2005-10-11
AU3841502A (en) 2002-06-24
US20020082260A1 (en) 2002-06-27
HRP20030450B1 (en) 2006-02-28
MXPA03005170A (es) 2003-09-22
DE60111570T2 (de) 2006-05-11
PL366006A1 (en) 2005-01-24
ES2243578T3 (es) 2005-12-01
PT1349856E (pt) 2005-09-30
NO325810B1 (no) 2008-07-21
TWI294876B (en) 2008-03-21
DE60111570D1 (de) 2005-07-21
PE20020593A1 (es) 2002-07-06
YU47703A (sh) 2006-05-25
JP4021766B2 (ja) 2007-12-12
CA2430579C (en) 2010-01-26
SK8732003A3 (en) 2004-04-06
BR0116169A (pt) 2003-12-23
UY27069A1 (es) 2002-07-31
WO2002048106A2 (en) 2002-06-20
US6482951B2 (en) 2002-11-19
ATE297922T1 (de) 2005-07-15
PA8534601A1 (es) 2002-08-26
NO20032674L (no) 2003-06-12
KR20030064817A (ko) 2003-08-02
HUP0400587A2 (hu) 2004-06-28
JP2004521095A (ja) 2004-07-15
WO2002048106A3 (en) 2002-11-28
CN1481382A (zh) 2004-03-10
CA2430579A1 (en) 2002-06-20
EP1349856B1 (en) 2005-06-15
AU2002238415B2 (en) 2007-01-04
NO20032674D0 (no) 2003-06-12
RU2249590C2 (ru) 2005-04-10
NZ526236A (en) 2004-12-24
IL156264A0 (en) 2004-01-04
HRP20030450A2 (en) 2005-04-30
MA26973A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
RS50933B (sr) Izoindolin-1-on aktivatori glukokinaze
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
CA2429642A1 (en) Fused heteroaromatic glucokinase activators
ATE340173T1 (de) Piperazin- und piperidin- derivate
DE68905979D1 (de) Antidepressive n-substitierte nikotinamid-verbindungen.
AR035639A1 (es) Derivados de para-aril o heterociclil sustituidos activadores de fenilglucoquinasa, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de medicamentos.
DE69942801D1 (de) Heterozyklische indolderivate und mono- oder diazaindol-derivate
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
HRP20010200B1 (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
CO5601027A2 (es) Derivados de imidazol-4-il-etinil-piridina
UA19304A (uk) Фуhгіцидhий засіб
BR0209334A (pt) Aminas n-aroil cìclicas
CA2250840A1 (en) Antivirally active heterocyclic azahexane derivatives
EA200400452A1 (ru) Производные 3-замещенных 4-пиримидонов
DK249089D0 (da) Benzamid-forbindelser, der er nyttige som protease-inhibitorer
WO2003031442A1 (fr) Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
CA2163028A1 (en) New thiazolidinediones and pharmaceutical agents containing them
WO2000005223A3 (en) Heterocyclic derivatives and their use as integrin inhibitors
NO931366D0 (no) 1,2,4-oksadiazolylfenoksyalkylisoksazoler og deres anvendelse som antivirale midler
UA66756C2 (uk) Сполуки піперазину та піперидину, спосіб одержання сполук та спосіб лікування розладів центральної нервової системи
NO901926D0 (no) Arylimidazoler med pesticid virkning, deres fremstilling og anvendelse.
ES2190252T3 (es) Derivados de 2-fenilpiran-4-ona.
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
NO20033131L (no) Anvendelse av 2-amino-4-pyridylmetyl-tiazolinderivater som inhibitorer forinduktibel NO-syntase
PE20060339A1 (es) Heterociclos monociclicos como inhibidores de cinasa